Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care

Sarcoma Clinical Trial

Official title:

Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04300257
• Other study ID #: 2019-01107
• Status: Recruiting
• Start date: October 19, 2019
• Est. completion date: December 31, 2029

Study information

• Verified date: March 2024
• Source: Kantonsspital Winterthur KSW
• Contact: Bruno Fuchs, Prof.
• Phone: +41 52 266 25 33
• Email: bruno.fuchs[@]ksw.ch
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The primary significance of this project is to perform a detailed analysis to assess the diagnostics, treatment and follow-up care, to develop a prediction model for future patient selection regarding various diagnostic and treatment procedures.

Description:

Within the framework of interdisciplinary cooperation for a sarcoma problem, predictive and prognostic criteria will be developed that improve the treatment and particularly outcome.

The outcome variables include patient characteristics, tumor types and characteristics, histology, management and treatment strategies as well as recurrence rate and overall survival.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: December 31, 2029
• Est. primary completion date: December 31, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Malignant and intermediate and selected benign bone or soft tissue tumors, acc. to the WHO coding list of the SSN

• Female and male subjects of all ages

Exclusion Criteria:

• Documented objection of subsequent use of personal health data

Related Conditions & MeSH terms

• Sarcoma

Locations

Country	Name	City	State
Switzerland	Ente Ospedaliero Cantonale	Bellinzona	Tessin
Switzerland	Kantonsspital Graubünden	Chur	Graubünden
Switzerland	Luzerner Kantonsspital	Lucerne
Switzerland	Kantonsspital Winterthur	Winterthur	Zuerich
Switzerland	SwissSarcomaNetwork	Winterthur	Zürich
Switzerland	Klinik Hirslanden	Zürich
Switzerland	Pathologie Institut Enge	Zürich
Switzerland	Stadtspital Zürich Triemli	Zürich

Sponsors (2)

Lead Sponsor	Collaborator
Kantonsspital Winterthur KSW	Swiss Sarcoma Network

Country where clinical trial is conducted

Switzerland, 

References & Publications (2)

Abarca T, Gao Y, Monga V, Tanas MR, Milhem MM, Miller BJ. Improved survival for extremity soft tissue sarcoma treated in high-volume facilities. J Surg Oncol. 2018 Jun;117(7):1479-1486. doi: 10.1002/jso.25052. Epub 2018 Apr 6. — View Citation

Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, Delgado Bolton R, Donati DM, Douis H, Haas R, Hogendoorn P, Kozhaeva O, Lavender V, Lovey J, Negrouk A, Pereira P, Roca P, de Lempdes GR, Saarto T, van Berck B, Vassal G, Wartenberg M, Yared — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnosis,	Data collected in the registry will be evaluated and analyzed to determine criteria to improve treatment strategies	5 years
Primary	Local recurrence,	s.o.	5 years
Primary	distant metastasis,	s.o.	5 years
Primary	biopsy taken by operating surgeon-radiologist-team,	s.o.	5 years
Primary	pathology centrally reviewed,	s.o.	5 years
Primary	Surgery (yes/no),	s.o.	5 years
Primary	Surgical margin status,	s.o.	5 years
Primary	surgery performed by dedicated surgeon,	s.o.	5 years
Primary	Radiation Therapy (yes/no),	s.o.	5 years
Primary	Chemotherapy (yes/no),	s.o.	5 years
Primary	decision of board carried out,	s.o.	5 years
Primary	Status at last contact,	s.o.	5 years